SynthesisJournal of Alzheimer's disease : JAD2020
From Polygenic Scores to Precision Medicine in Alzheimer's Disease: A Systematic Review.
Synthesis in Journal of Alzheimer's disease : JAD, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Manifestations of Alzheimer's disease genetic risk in the blood are evident in a multiomic analysis in healthy adults aged 18 to 90.Scientific reports · 2022Pooled it
- Genetic background and multidomain interventions in mild cognitive impairment.Alzheimer's research & therapy · 2025Trial
- A Genome-wide Association Study of Alzheimer's Disease and Dementia in a Large Multi-ancestry Military Cohort Identifies Many New Dementia-Associated Loci.medRxiv : the preprint server for health sciences · 2026Article
- Toward personalized medicine in AD/ADRD through genetic-exposome dementia risk assessments.NPJ dementia · 2026Review
- Alzheimer's disease polygenic risk's association with all-cause dementia through the plasma metabolome in the UK Biobank study.GeroScience · 2025Article
- Polygenic score integrating neurodegenerative and vascular risk informs dementia risk stratification.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- White matter microstructure in mid- to late adulthood is influenced by pathway-stratified polygenic risk for Alzheimer's disease.Frontiers in neuroscience · 2025Article
- Effects of transcranial direct current stimulation on cognition in MCI with Alzheimer's disease risk factors using Bayesian analysis.Scientific reports · 2024Article
- Genetic risk score for Alzheimer's disease predicts brain volume differences in mid and late life in UK biobank participants.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Artificial Intelligence in Cardiology and Atherosclerosis in the Context of Precision Medicine: A Scoping Review.Applied bionics and biomechanics · 2024Article
- Epistatic Features and Machine Learning Improve Alzheimer's Disease Risk Prediction Over Polygenic Risk Scores.Journal of Alzheimer's disease : JAD · 2024Article
- Addressing overlapping sample challenges in genome-wide association studies: Meta-reductive approach.PloS one · 2024Article
- Transcranial direct current stimulation and neuronal functional connectivity in MCI: role of individual factors associated to AD.Frontiers in psychiatry · 2024Article
- Emerging Microglial Therapies and Targets in Clinical Trial.Advances in neurobiology · 2024Review
- Addressing Overlapping Sample Challenges in Genome-Wide Association Studies: Meta-Reductive Approach.bioRxiv : the preprint server for biology · 2023Article
- Improved multimodal prediction of progression from MCI to Alzheimer's disease combining genetics with quantitative brain MRI and cognitive measures.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- Overestimated prediction using polygenic prediction derived from summary statistics.BMC genomic data · 2023Article
- Evaluating the Classification Accuracy of Expression Quantitative Trait Loci Calculated Polygenic Risk Scores in Alzheimer's Disease.International journal of molecular sciences · 2023Article
- Personalising Alzheimer's Disease progression using brain atrophy markers.medRxiv : the preprint server for health sciences · 2023Article
- Polygenic Risk Scores for Alzheimer's Disease and General Cognitive Function Are Associated With Measures of Cognition in Older South Asians.The journals of gerontology. Series A, Biological sciences and medical sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundLate-onset Alzheimer's disease (AD) is highly heritable. The effect of many common genetic variants, single nucleotide polymorphisms (SNPs), confer risk. Variants are clustered in areas of biology, notably immunity and inflammation, cholesterol metabolism, endocytosis, and ubiquitination. Polygenic scores (PRS), which weight the sum of an individual's risk alleles, have been used to draw inferences about the pathological processes underpinning AD.
objectiveThis paper aims to systematically review how AD PRS are being used to study a range of outcomes and phenotypes related to neurodegeneration.
methodsWe searched the literature from July 2008-July 2018 following PRISMA guidelines.
results57 studies met criteria. The AD PRS can distinguish AD cases from controls. The ability of AD PRS to predict conversion from mild cognitive impairment (MCI) to AD was less clear. There was strong evidence of association between AD PRS and cognitive impairment. AD PRS were correlated with a number of biological phenotypes associated with AD pathology, such as neuroimaging changes and amyloid and tau measures. Pathway-specific polygenic scores were also associated with AD-related biologically relevant phenotypes.
conclusionPRS can predict AD effectively and are associated with cognitive impairment. There is also evidence of association between AD PRS and other phenotypes relevant to neurodegeneration. The associations between pathway specific polygenic scores and phenotypic changes may allow us to define the biology of the disease in individuals and indicate who may benefit from specific treatments. Longitudinal cohort studies are required to test the ability of PGS to delineate pathway-specific disease activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.